2,6-dimethyl-3-methylthiopyridine | 116651-87-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2,6-dimethyl-3-methylthiopyridine
• 英文别名: 2,6-Dimethyl-3-methylsulfanylpyridine
• CAS: 116651-87-7
• 化学式: C₈H₁₁NS
• 分子量: 153.248
• InChiKey: TWNQVKMOLBKVRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  209.1±28.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-3-methylthiopyridine 在 双氧水 、 溶剂黄146 、 三氟乙酸酐 作用下， 反应 4.17h， 生成 2,6-dimethyl-3-methylsulfonylpyridine
  参考文献：
  名称：

  Ban-Oganowska, H., Polish Journal of Chemistry, 1993, vol. 67, # 9, p. 1609 - 1614

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-二甲基-3-溴吡啶 在 双氧水 、 copper diacetate 、 乙酸酐 、 三溴化磷 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 12.5h， 生成 2,6-dimethyl-3-methylthiopyridine
  参考文献：
  名称：

  Ban-Oganowska, H., Polish Journal of Chemistry, 1993, vol. 67, # 9, p. 1609 - 1614

  摘要：

  DOI：

文献信息

• Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
  申请人：CHEMOCENTRYX, INC.

  公开号：US11304952B2

  公开（公告）日：2022-04-19

  The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.

  本公开涉及化合因子受体 2 (CCR2) 拮抗剂与 PD-1 和/或 PD-L1 抑制剂在治疗癌症方面的联合疗法。
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property(No.2)Limited

  公开号：US20190048016A1

  公开（公告）日：2019-02-14

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
  申请人：CHEMOCENTRYX, INC.

  公开号：US20190134049A1

  公开（公告）日：2019-05-09

  The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
• COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES
  申请人：KYULUX, INC.

  公开号：US20200203622A1

  公开（公告）日：2020-06-25

  The present disclosure relates to compounds of Formula (I)-(V) as compounds capable of emitting delayed fluorescence and uses of these compounds in organic light-emitting diodes.
• [EN] IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF<br/>[FR] IMIDAZOPYRIMIDINES UTILISÉES EN TANT QU'INHIBITEURS DE EED ET LEUR UTILISATION
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021011713A1

  公开（公告）日：2021-01-21

  The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.